Amedisys (Nasdaq: AMED) reported earnings on April 30. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Amedisys missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.

Gross margins grew, operating margins contracted, net margins contracted.

Revenue details
 Amedisys reported revenue of $339.2 million. The 10 analysts polled by S&P Capital IQ foresaw a top line of $358.5 million on the same basis. GAAP reported sales were 7.1% lower than the prior-year quarter's $365.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.13. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.18 per share. Non-GAAP EPS of $0.13 for Q1 were 41% lower than the prior-year quarter's $0.22 per share. (The prior-year quarter included -$0.04 per share in earnings from discontinued operations.) GAAP EPS of $0.09 for Q1 were 50% lower than the prior-year quarter's $0.18 per share. (The prior-year quarter included -$0.04 per share in earnings from discontinued operations.)

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 43.2%, 30 basis points better than the prior-year quarter. Operating margin was 1.2%, 220 basis points worse than the prior-year quarter. Net margin was 0.8%, 70 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $358.8 million. On the bottom line, the average EPS estimate is $0.16.

Next year's average estimate for revenue is $1.44 billion. The average EPS estimate is $0.65.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 812 members out of 899 rating the stock outperform, and 87 members rating it underperform. Among 200 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 173 give Amedisys a green thumbs-up, and 27 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $10.67.

Is Amedisys the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.